Surgical Fetal Stem Cell Transplant into Heart Failure Patients Long-term Results at 14 Years
Article Sidebar
Main Article Content
Abstract
Direct myocardial transplant of HFDSCs (human fetal derived stem cells) by open chest surgical procedure was performed in 10 patients with Heart Failure (HF) due to no ischemic, no chagasic dilated cardiomyopathy. All 10 patients survived the operation. At 40 months, the mean (±SD) NYHA class decreased from 3.4 ± 0.5 to 1.33 ± 0.5 (p = .001); the mean EF increased 31%, from 26.6% ± F) 34.8% ± 7.2% (p = .005); and the mean ETT increased 291.3%, from 4.25 minutes to 16.63 minutes (128.9% increase in metabolic equivalents, from 2.46 to 5.63) (p < .0001); the mean LVEDD decreased 15%, from 6.85 ± 0.6 cm to 5.80 ± 0.58 cm (p < .001); mean performance in the 6-minute walk test increased by 43.2%, from 251 ± 113.1 seconds to 360 0 seconds (p = .01); the mean distance increased 64.4%, from 284.4 144.9 m to 468.2 ± 89.8 m (p = .004); and the mean result in the Minnesota test decreased from 71 ± 27.3 to 6 ± 5.9 (p < .001). Six patients survived after 40 months; 5 of them had complete reverse remodeling after 3 months after transplants. The average age at the moment of the transplants was 62 years (s/d 11.6).
Results: The first patient died at 5,4 years for an infection; the second patient died at,7,4 years for heart failure; the third patient died at 8,4 years for heart failure; the fourth patient died at 10 years for heart failure and the fifth patient died at 14,4 years after transplant at the age of 83 for heart failure. The average age at the moment of death was 70 years (s/d12.9). The survival rate at 4 years was 100% (K/M) and at 14 years (25%K/M).
Conclusion: These initial worldwide experiences with the surgical direct transplant of liver fetal stem cells in patients with end-stage HF shows clearly the positive effect in the reverse remodeling of the left ventricle of 50% of the cohort and excellent long-term results in these types of patients opening a new avenue for treating end-stage HF patients without any other option of treatment.
Article Details
Copyright (c) 2025 Benetti F, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Journal of Stem Cell Therapy and Transplantation is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Journal of Stem Cell Therapy and Transplantation is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
Remme WJ, Swedberg K, Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527-1560. Available from: https://doi.org/10.1053/euhj.2001.2783
Colucci W, Braunwald E. Pathophysiology of heart failure. In: Braunwald E, editor. Heart Disease. 5th ed. Philadelphia: WB Saunders; 1997;360-393.
Carbajal EV, Deedwani PC. Congestive heart failure. In: Deedwani PC, editor. Current Diagnosis and Treatment in Cardiology. 2nd ed. New York: McGraw-Hill; 2003;18.
Bolling SF, Pagani FD, Deeb GM. Intermediate-term outcome of mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg. 1998;115(2):381-386. Available from: https://doi.org/10.1016/s0022-5223(98)70282-x
Wang JS, Shum D, Galipeau J. Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. J Thorac Cardiovasc Surg. 2000;120(5):999-1005. Available from: https://doi.org/10.1067/mtc.2000.110250
Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003;9(6):702-712. Available from: https://doi.org/10.1038/nm0603-702
Orlic D, Kassutra J, Chimenti S, Jakoniuk I, Anderson SM, Li B. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410:701-705. Available from: https://doi.org/10.1038/35070587
Edelberg JM, Tang L, Hattori K, Lyden D, Rafii S. Young adult bone marrow-derived endothelial precursor cells restore aging-impaired cardiac angiogenic function. Circ Res. 2002;E89-E93. Available from: https://doi.org/10.1161/01.RES.0000020861.20064.7E
Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Isliura A, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood. 1998;92:362-367. Available from: https://doi.org/10.1182/blood.V92.2.362
Sata M, Saiura A, Kunisato A, Tojo A, Okara S, Tokuhisa T, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002;8:403-409. Available from: https://doi.org/10.1038/nm0402-403
Otani A, Kinder K, Ewalt K, Otero S, Tokuhisa T, Tirai H, et al. Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat Med. 2002;8:1004-1010. Available from: https://doi.org/10.1038/nm744
Young PP, Hofling AA, Sands MS. VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipients. Proc Natl Acad Sci U S A. 2002;99:11951-11956. Available from: https://doi.org/10.1073/pnas.182215799
Nigro P, Bassetti B, Cavallotti L, Catto V, Carbucicchio C, Pompilio G. Cell therapy for heart disease after 15 years: Unmet expectations. Pharmacol Res. 2018 Jan;127:77-91. Available from: https://doi.org/10.1016/j.phrs.2017.02.015
Yagyu T, Yasuda S, Nagaya N, Doi K, Nakatani T, Satomi K, et al. Long-term results of intracardiac mesenchymal stem cell transplantation in patients with cardiomyopathy. Circ J. 2019 Jun 25;83(7):1590-1599. Available from: https://doi.org/10.1253/circj.CJ-18-1179
Nakamura K, Murry CE. Function follows form - A review of cardiac cell therapy. Circ J. 2019 Nov 25;83(12):2399-2412. Available from: https://doi.org/10.1253/circj.cj-19-0567
Bartunek J, Terzic A, Davison BA, Behfar A, Sanz-Ruiz R, Wojakowski W, et al. Cardiopoietic stem cell therapy in ischemic heart failure: long-term clinical outcomes. ESC Heart Fail. 2020;7(6):3345-3354. Available from: https://doi.org/10.1002/ehf2.13031
Le DC, Bui HT, Vu YT, Vo QD. Induced pluripotent stem cell therapies in heart failure treatment: A meta-analysis and systematic review. Regen Med. 2024;19(9-10):1-13. Available from: https://doi.org/10.1080/17460751.2024.2393558
Benetti F, Peñherrera E, Maldonado T, Vera YD, Subramanian V, Geffner L. Direct myocardial implantation of human fetal stem cells in heart failure patients: long-term results. Heart Surg Forum. 2010 Feb;13(1):E31-5. Available from: https://doi.org/10.1532/hsf98.20091130
Meerson FZ. The myocardium in hyperfunction, hypertrophy, and heart failure. Circ Res. 1969;25(suppl 2):1-163. Available from: https://pubmed.ncbi.nlm.nih.gov/4240407/
Zak R. Cardiac hypertrophy: biochemical and cellular relationships. Hosp Pract. 1983;18:85-97. Available from: https://doi.org/10.1080/21548331.1983.11702494
Colucci WS, Braunwald E. Pathophysiology of heart failure. In: Braunwald E, editor. Braunwald’s Heart Disease. 5th ed. Saunders; 1997.
Wynne J, Braunwald E. The cardiomyopathies and myocarditis. In: Braunwald E, editor. Braunwald’s Heart Disease. 5th ed. Saunders; 1997.
Prokop D. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276:71-74. Available from: https://doi.org/10.1126/science.276.5309.71
Boxall SA, Jones E. Markers for characterization of bone marrow multipotential stromal cells. Stem Cells Int. 2012;2012:975871. Available from: https://doi.org/10.1155/2012/975871
Masson NM, Currie IS, Terrace JD, Garden OJ, Parks RW, Ross JA. Hepatic progenitor cells in human fetal liver express the oval cell marker Thy-1. Am J Physiol Gastrointest Liver Physiol. 2006 Jul;291(1):G45-54. Available from: https://doi.org/10.1152/ajpgi.00465.2005
Pittenger MF, Makay A, Beck SC, Jaiwasal RK, Douglas R, Mosca JD, et alDR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147. Available from: https://doi.org/10.1126/science.284.5411.143
Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest. 1999;105(5):697-705. Available from: https://doi.org/10.1172/jci5298
Xu M, Wani M, Dai YS, Wang J, Yan M, Ayub A, et al. Differentiation of bone marrow stromal cells into cardiac phenotype requires intracellular communication with myocytes. Circulation. 2004;110:2658-2665. Available from: https://doi.org/10.1161/01.cir.0000145609.20435.36
Chedway EG, Wang JS, Nguyen DM, Shum-Tim J, Chiu RCJ. Incorporation and integration of implanted myogenic and stem cells into native myocardial fibers: anatomic basis for functional improvements. J Thorac Cardiovasc Surg. 2002;124(3):584-590. Available from: https://doi.org/10.1067/mtc.2002.122544
Pittenger MF, Bradley JM. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res. 2004;95:9-20. Available from: https://doi.org/10.1161/01.RES.0000135902.99383.6f
Yau TM, Tomita S, Weisel RD, Jia ZQ, Tumiati LC, Mickle DA, et al. Beneficial effect of autologous cell transplantation on infarcted heart function: comparison between bone marrow stromal cells and heart cells. Ann Thorac Surg. 2003;75:169-177. Available from: https://doi.org/10.1016/s0003-4975(02)04290-x
Fazel S, Tang GHL, Angoulvant D. Current status of cellular therapy for ischemic heart disease. Ann Thorac Surg. 2005 Jun;79(6):S2238-47. Available from: https://doi.org/10.1016/j.athoracsur.2005.02.085
Sakakibara Y, Nishimura K, Tambara K, Yamamoto M, Lu F, Tabata Y, et al. Prevascularization with gelatin microspheres containing basic fibroblast growth factor enhances the benefits of cardiomyocyte transplantation. J Thorac Cardiovasc Surg. 2002;124(1):50-56. Available from: https://doi.org/10.1067/mtc.2002.121293
Yamamoto M, Sakakibara Y, Nishimura K, Komeda M, Tabata Y. Improved therapeutic efficacy in cardiomyocyte transplantation for myocardial infarction with release system of basic fibroblast growth factor. Artif Organs. 2003;27(2):181-184. Available from: https://doi.org/10.1046/j.1525-1594.2003.06993.x
Tambara K, Sakakibara Y, Sakaguchi G, Lu F, Premaratne GU, Lin X, et al. Transplanted skeletal myoblasts can fully replace the infarcted myocardium when they survive in the host in large numbers. Circulation. 2003;108(Suppl II):II259-II263. Available from: https://doi.org/10.1161/01.cir.0000087430.17543.b8
Nakajima H, Sakakibara Y, Tambara K, Iwakura A, Doi K, Marui A, et al. Therapeutic angiogenesis by the controlled release of basic fibroblast growth factor for ischemic limb and heart injury: toward safety and minimal invasiveness. J Artif Organs. 2004;58-61. Available from: https://doi.org/10.1007/s10047-004-0252-1
Marui A, Tabata Y, Kojima S, Yamamoto M, Tambara K, Nishina T, et al. A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel: an initial report of the phase I-IIa study. Circ J. 2007;71(8):1181-6. Available from: https://doi.org/10.1253/circj.71.1181
Komeda M, Marui A, Tambara K, Yamamoto M, Saji Y, Nishina T, et al. Biologic anastomosis: the first case of biologic coronary bypass surgery. J Thorac Cardiovasc Surg. 2009;138:775-777. Available from: https://doi.org/10.1016/j.jtcvs.2008.05.066
Sakakibara Y, Tambara K, Sakaguchi G, Lu F, Yamamoto M, Nishimura K, et al. Toward surgical angiogenesis using slow-released basic fibroblast growth factor. Eur J Cardiothorac Surg. 2003;24(1):105-112. Available from: https://doi.org/10.1016/s1010-7940(03)00159-3
Tambara K, Tabata Y, Komeda M. Factors related to the efficacy of skeletal muscle cell transplantation and future approaches with controlled-released cell growth factors and minimally invasive surgery. Int J Cardiol. 2004;95:S13-S15. Available from: https://doi.org/10.1016/S0167-5273(04)90004-6
Kung JW, Currie IS, Forbes SJ, Ross JA. Liver development, regeneration, and carcinogenesis. J Biomed Biotechnol. 2010;2010:984248. Available from: https://doi.org/10.1155/2010/984248